Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort /

S Koirala; S Borisov; Edvardas Danila; A Mariandyshev; B Shrestha; N Lukhele; M Dalcolmo; S R Shakya; Skaidrius Miliauskas; L Kuksa; S Manga; A Aleksa; J T Denholm; H B Khadka; A Skrahina; S Diktanas; M Ferrarese; J Bruchfeld; A Koleva; A Piubello; G S Koirala; Z F Udwadia; D J Palmero; M Munoz-Torrico; R Gc; G Gualano; V I Grecu; I Motta; A Papavasileiou; Y Li; W Hoefsloot; H Kunst; J Mazza-Stalder; M-C Payen; O W Akkerman; E Bernal; V Manfrin; A Matteelli; H Mustafa Hamdan; M Nieto Marcos; J Cadiñanos Loidi; J J Cebrian Gallardo; R Duarte; N Escobar Salinas; R Gomez Rosso; R Laniado-Laborín; E Martínez Robles; S Quirós Fernandez; A Rendon; I Solovic; M Tadolini; P Viggiani; E Belilovski; M J Boeree; Q Cai; E Davidavičienė; L D Forsman; J De Los Rios; J Drakšienė; A Duga; S E Elamin; A Filippov; A Garcia; I Gaudiesiute; B Gavazova; R Gayoso; Vygantas Gruslys; J Jonsson; E Khimova; G Madonsela; C Magis-Escurra; V Marchese; M Matei; C Moschos; B Nakčerienė; L Nicod; F Palmieri; A Pontarelli; A Šmite; M B Souleymane; M Vescovo; Rolandas Zablockis; D Zhurkin; J-W Alffenaar; J A Caminero; L R Codecasa; J-M García-García; S Esposito; L Saderi; A Spanevello; D Visca; S Tiberi; E Pontali; R Centis; L D'Ambrosio; M van den Boom; G Sotgiu; G B Migliori

doi:10.1016/j.pulmoe.2021.02.006

Title	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort /
Authors	Koirala, S ; Borisov, S ; Danila, Edvardas ; Mariandyshev, A ; Shrestha, B ; Lukhele, N ; Dalcolmo, M ; Shakya, S R ; Miliauskas, Skaidrius ; Kuksa, L ; Manga, S ; Aleksa, A ; Denholm, J T ; Khadka, H B ; Skrahina, A ; Diktanas, S ; Ferrarese, M ; Bruchfeld, J ; Koleva, A ; Piubello, A ; Koirala, G S ; Udwadia, Z F ; Palmero, D J ; Munoz-Torrico, M ; Gc, R ; Gualano, G ; Grecu, V I ; Motta, I ; Papavasileiou, A ; Li, Y ; Hoefsloot, W ; Kunst, H ; Mazza-Stalder, J ; Payen, M-C ; Akkerman, O W ; Bernal, E ; Manfrin, V ; Matteelli, A ; Mustafa Hamdan, H ; Nieto Marcos, M ; Cadiñanos Loidi, J ; Cebrian Gallardo, J J ; Duarte, R ; Escobar Salinas, N ; Gomez Rosso, R ; Laniado-Laborín, R ; Martínez Robles, E ; Quirós Fernandez, S ; Rendon, A ; Solovic, I ; Tadolini, M ; Viggiani, P ; Belilovski, E ; Boeree, M J ; Cai, Q ; Davidavičienė, E ; Forsman, L D ; De Los Rios, J ; Drakšienė, J ; Duga, A ; Elamin, S E ; Filippov, A ; Garcia, A ; Gaudiesiute, I ; Gavazova, B ; Gayoso, R ; Gruslys, Vygantas ; Jonsson, J ; Khimova, E ; Madonsela, G ; Magis-Escurra, C ; Marchese, V ; Matei, M ; Moschos, C ; Nakčerienė, B ; Nicod, L ; Palmieri, F ; Pontarelli, A ; Šmite, A ; Souleymane, M B ; Vescovo, M ; Zablockis, Rolandas ; Zhurkin, D ; Alffenaar, J-W ; Caminero, J A ; Codecasa, L R ; García-García, J-M ; Esposito, S ; Saderi, L ; Spanevello, A ; Visca, D ; Tiberi, S ; Pontali, E ; Centis, R ; D'Ambrosio, L ; van den Boom, M ; Sotgiu, G ; Migliori, G B
DOI	10.1016/j.pulmoe.2021.02.006
Full Text
Is Part of	Pulmonology.. Amsterdam : Elsevier. 2021, vol. 7, no. 5, p. 403-412.. eISSN 2531-0437
Keywords [eng]	bedaquiline ; delamanid ; MDR-TB ; prevention of TB sequelae ; treatment outcomes ; tuberculosis
Abstract [eng]	The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.
Published	Amsterdam : Elsevier
Type	Journal article
Language	English
Publication date	2021
CC license

„Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort /“